Sensitivity of a Preclinical Alzheimer’s Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer’s disease.
Introduction: Preclinical Alzheimer’s disease (AD) is characterized by amyloid-related cognitive decline. Reduction in this decline is used to determine the efficacy of drug therapies designed to forestall the disease in preclinical AD clinical trials, measured by […]
Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia.
INTRODUCTION: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer’s disease (AD) and non-AD dementia and (2) determinants of progression to dementia. METHODS: […]
Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer’s disease: Findings from three well-characterized cohorts.
INTRODUCTION: Our objective was to investigate the effect of sex on cognitive decline within the context of amyloid β (Aβ) burden and apolipoprotein E genotype. METHODS: We analyzed sex-specific effects on Aβ-positron emission tomography, apolipoprotein, and […]
Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis.
INTRODUCTION: This meta-analysis aimed to characterize the nature and magnitude of amyloid (Aβ)-related cognitive impairment and decline in cognitively normal (CN) older individuals. METHOD: MEDLINE Ovid was searched from 2012 to June 2016 for studies reporting […]
Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer’s Disease.
It is not known whether computerized cognitive assessments, like the CogState battery, are sensitive to preclinical cognitive changes or pathology in people at risk for Alzheimer’s disease(AD). In 469 late middle-aged participants from the Wisconsin Registry […]